11/4
08:42 am
prqr
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Medium
Report
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
11/4
08:25 am
prqr
Rating for PRQR
Medium
Report
Rating for PRQR